1. 1. World Health Organization. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitisc
2. 2. Accelerating access to hepatitis C diagnostics and treatment: overcoming barriers in low- and middle-income countries. Global progress report 2020. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.
3. 3. Annex 1. Summary of product characteristics. In: Maviret EPAR product information. European Medicine Agency; 2017. Available from: https://www.ema.europa.eu/en/documents/product-information/maviret-epar product ınformatıon an pdf. Accessed 10 April 2022.
4. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection;Zeuzem;N Engl J Med,2018
5. Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy;Grebely;Int J Drug Policy,2019